-
Rat Alpha 2 Macroglobulin ELISACatalog #: 41-A2MRT-E01
Sensitivity: 6.24 ng/mL
Range: 6.25 - 400 ng/mL
Sample Types: Plasma, Serum
Sample Size(s): 96 Wells
Detection: Colorimetric -
Rat Alpha 1 Acid Glycoprotein ELISA
Catalog #: 41-AGPRT-E01
Sensitivity: 12.5 ng/mL
Range: 12.5 - 400 ng/mL
Sample Types: Plasma, Serum
Sample Size(s): 96 Wells
Detection: Colorimetric -
Mouse Alpha 1-Antitrypsin ELISA
Catalog #: 41-A1AMS-E01
Sensitivity: 6.25 ng/mL
Range: 6.25 - 200 ng/mL
Sample Types: Serum
Sample Size(s): 96 Wells
Detection: Colorimetric -
Mouse Haptoglobin ELISA
Catalog #: 41-HAPMS-E01
Sensitivity: 5 ng/mL
Range: 7.81 - 125 ng/mL
Sample Types: Plasma, Serum
Sample Size(s): 96 Wells
Detection: Colorimetric -
Mouse Complement Factor 3 ELISA
Catalog #: 41-CO3MS-E01
Sensitivity: 3.125 ng/mL
Range: 3.125 - 200 ng/mL
Sample Types: Plasma, Serum
Sample Size(s): 96 Wells
Detection: Colorimetric
Responsibility
ALPCO’s Diabetes Research Travel GrantALPCO strives to provide scientists and healthcare professionals with robust tools for their research and clinical diagnostic endeavors. We understand that championing extraordinary discoveries requires extraordinary efforts, and support. We are proud to continu...
Alpco Home Page
New: Calprotectin Immunoturbidimetric Assay will take your testing to the next level. Learn more.Supporting your work with life science and clinical testing productsVIEW ALL LIFE SCIENCE PRODUCTSVIEW ALL CLINICAL DIAGNOSTIC PRODUCTS
Tips & Tricks
The Enzyme-Linked Immunosorbent Assay (ELISA) is a proven sensitive method for detecting and quantifying specific biomarkers in a wide range of clinical and research samples. The accuracy and precision of ELISAs can be affected by many factors, including pipetting, washing, and sample-handling techn...
Company Overview
Accuracy and Efficiency. Together.We are a leading global developer and provider of innovative molecular and immunodiagnostic products focused on Infectious and Gastroenterological Diseases. We are a trusted partner creating value for research and clinical laboratories with high-quality, user-frien...
Stool-Based Biomarkers to Differentiate Between IBD and IBS
What are IBD and IBS?
Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are two different gastrointestinal tract issues affecting millions of people every day. Although there is some overlap between symptoms of IBD and IBS, differences still remain in regards to pathologies, risks...
Differentiating Gastrointestinal Pathogens from IBD and IBS
Gastrointestinal (GI) disorders such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), as well as infections from GI pathogens can present very similar symptoms. A host of tests have been developed to aid in the differentiation between IBD and IBS, such as calprotectin and lact...
Complement System Webinar
Dr. Jörgen Wieslander from our partner, Euro Diagnostica, discusses functional assessment of all three pathways of the complement system.
https://www.youtube.com/watch?v=afJwUGoN99M
Complement System Solutions for Drug Development and Clinical Research
Datasheet: Complement System Immunoassays
Download
The complement system is essential to innate immunity which protects from chronic, autoimmune, and infectious disease. There are three distinct pathways of complement activation: classical, lectin/MBL, and alternative. Each leads...
Toxicology
Drug-Induced Organ Injury
Toxicological side effects are a common obstacle in drug development pipelines and often manifest in site-specific damage to vital organs, including the liver, kidney and heart. Estimates of compound attrition from failure to meet safety endpoints are as high as 45% in pre...
ALPCO and Cisbio US, Inc. Announce Sales and Distribution Agreement
Date: July 1, 2015
ALPCO is pleased to announce a strategic account sales and distribution agreement with Cisbio US, Inc. Cisbio will now have exclusive access to ALPCO’s high quality STELLUX® Chemiluminescence and colorimetric Diabetes and Obesity assay portfolio in order to provide these produc...
Simplify Stool Sample Processing
Introduction
We understand the challenges facing lab managers and directors who need to continuously improve workflow efficiency and implement new tests and technologies to be competitive. Our unique extraction method can be used with a portfolio of targeted stool markers. This allows your lab to s...
New Stool-Based Gastroenterology Assays and Extraction Method Can Improve Lab Sample Processing Time By Up To 86%
Date: January 26, 2016
ALPCO recently launched a new panel of 13 stool-based gastroenterology assays that are all compatible with one single extraction step. The unique extraction method allows laboratories to improve their sample processing time by up to 86% by extracting one sample for up to 13...
Heart Disease Biomarkers in Diabetes Research
Introduction
Cardiovascular disease (CVD) encompasses a constellation of diseases related to the heart and circulatory system. Despite efforts to understand and combat CVD complications from diabetes, 65% of diabetics will pass away from cardiovascular issues1. Part 2 of The Common Denominator eBoo...
Physiological Actions of Natriuretic Peptides
Introduction
Humans have at least 50 discovered hormones managing vital biological functions in the body. These hormones are produced by the body’s organs and glands. Natriuretic peptides (NPs) are structurally related hormones synthesized and released from the heart, including atrial natriuretic p...
Early Detection of Diabetic Kidney Disease with Biomarkers
Introduction
Over one third of diabetics will develop diabetic kidney disease (DKD) in their lifetime1. Despite the large amount of diabetics suffering from DKD, current methods for measuring and tracking kidney function may not be specific enough for diabetic systems2,3.
Part III of The Common ...
ALPCO Releases a New Broad Range Periostin ELISA
ALPCO is now offering a new broad range Periostin ELISA that has been optimized to detect all known splicing forms of human periostin. The Periostin ELISA is highly characterized with a full validation package, and offers great reproducibility and precision. Not only are all standards and controls i...
The Changing Roles of Bone Remodeling Biomarkers
Introduction
Bones are traditionally known for their support, protection and movement properties, as well as their role in the processes of mineral balance and blood cell production. Research supports that bones do more than they were originally recognized for. Previous research investigating osteo...
[Infographic] The Benefits of Therapeutic Drug Monitoring for IBD
The Burden of Inflammatory Bowel Disease in the US and Canada
More than 1 million people in the US and 200,000 people in Canada are currently living with inflammatory bowel disease (IBD). This number is projected to grow exponentially over the next 10 years1,2. As the prevalence of IBD increases, s...
Emerging Biomarker Research in NAFLD and NASH
Nonalcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver disease in the western hemisphere affecting 1 in 3 adults and 1 in 10 children1. Today, liver biopsies are the only gold standard for precise diagnosis of NAFLD2. Because of this, there are tremendous efforts on the ...
The Impact of Adiponectin in NAFLD and NASH Research
Date: March 7, 2017
Lately, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have been widely discussed in both the clinical and research communities. Some of the focus has been related to alternative research methods that can improve diagnostic and monitoring meth...
New Zonulin ELISAs and Therapeutic Drug Monitoring Assays for IBD to be Launched at Digestive Disease Week®
We are excited to announce that we will launch new gastrointestinal and inflammatory bowel disease (IBD) assays at Digestive Disease Week® May 7-9, 2017 in Chicago, IL. Included in this release are the Zonulin Stool ELISA and Zonulin Serum ELISA to aid in the study of gut permeability and celiac dis...
Investigating Immunogenicity of IBD Biologics
Biologics have been commonly prescribed as therapies for inflammatory bowel disease (IBD) since the late 1990s. However, research demonstrates that not all individuals respond to the first biologic taken and many lose response over time1. As a result, there is a great need to explore the immunogenic...
IBS Awareness Month: Facts About IBS
In support of IBS Awareness Month, we created this short video to share some important facts about IBS and spread the word about this incurable, debilitating disorder.
Be sure to like and share our video to show your support of IBS Awareness Month!
https://youtu.be/6K_55Bg922s
Quick Facts Abo...
Introducing the STELLUX® Chemi Active GLP-1 (7-36) amide ELISA
Watch our video to learn more about the STELLUX® Chemi Active GLP-1 (7-36) amide ELISA and how you can now measure this incretin hormone with confidence.
https://www.youtube.com/watch?v=Chu3VhEEpt0&t=3s
The STELLUX® Chemi Active GLP-1 (7-36) amide ELISA features increased sensitivity to ac...